Table IV.
Previous studies on complications and survival outcome in patients with salvage surgery after chemoradiotherapy for squamous cell carcinoma of the hypopharynx and larynx.
| Authors | Year | N | Site | Comp | Fistula | LR | OS | DSS | Remarks |
|---|---|---|---|---|---|---|---|---|---|
| Stoeckli 7 | 2000 | 36 | L | 28% | 14% | 63% (5 y) | RT and CRT | ||
| Stoeckli 7 | 2000 | 9 | H | 40% | 11% | 20% (5 y) | RT and CRT | ||
| Leon 14 | 2001 | 28 | L | 21% | 17% | 57% (5 y) | endoresection | ||
| Weber 35 | 2003 | 75 | L | ~59% | ~30% | 74% (2 y) | 69-71% (2 y) | ||
| Ganly 26 | 2005 | 38 | L | 53% | 32% | ||||
| Clark 13 | 2006 | 138 | L/H | 70% (salvage) |
31% | 31% (5 y) (salvage) |
PT: none, RT, CRT | ||
| Fung 20 | 2007 | 14 | L | 29% | Interposition graft. ngopharyngectomy defects |
||||
| Furuta 44 | 2008 | 34 | L | 47% wound | 24% | ||||
| Gil 5 | 2009 | 18 | L | 39% | PL/TL, RT and CRT | ||||
| Patel 6 | 2009 | 17 | L | 24% | CRT or RT? | ||||
| Relic 45 | 2009 | 16 | L/H | 73% | 38% (3 y) | 1 PL | |||
| Tsou 8 | 2010 | 48 | H | 58% | |||||
| Paleri* 46 | 2011 | >350 | L | 87% (2 y) | 83% (3 y) | 91% (2 y) | RT and CRT, PL | ||
| vd Putten 15 | 2011 | 120 | L | 70% (5 y) 79% (5 y) regional |
50% (5 y) | 58% (5 y) | RT and CRT, TL | ||
| Klozar 47 | 2012 | 208 | L/H | 34% | RT and CRT | ||||
| Sewnaik 48 | 2012 | 24 | L/H | 92% | |||||
| Patel 9 | 2013 | 359 | L/H | 27% | RT and CRT, primLE | ||||
| Li 12 | 2013 | 100 | L | 70% (5 y) | 55-70% (5 y) | RT and CRT, survival | |||
| Basheeth 49 | 2013 | 45 | L/H | 44% | Major complications, N0 | ||||
| Suzuki 50 | 2013 | 24 | H | 33% | 50% (2 y) | ||||
| Sayles* 10 | 2014 | 33 st | L/H | 34% | |||||
| Timmermans 31 | 2014 | 98 | L/H | 26% | RT and CRT, primLE | ||||
| Omura 51 | 2014 | 42 | H | 40% (3 y) | RT and CRT, ICT | ||||
| Powell 52 | 2014 | 45 | L/H | 22% | |||||
| Suslu 11 | 2015 | 151 | L/H | 13% | RT and CRT, ICT | ||||
| Sassler 30 | 1995 | 18 | HN | 61% major | 50% | Sequential CRT | |||
| Newman 53 | 1997 | 17 | HN | 35% | 20% | ||||
| Lavertu 34 | 1998 | 26 | HN | 46% | 4% | ||||
| Goodwin 37 | 2000 | 109 | HN | 20% | 6% | Med 21.5 months | PT: surgery, RT, CRT (17%) | ||
| Goodwin* 37 | 2000 | 1633 | HN | 39% | 39% (5 y) | PT: surgery, RT, CRT | |||
| Agra 54 | 2003 | 124 | HN | 78% (CRT) | PT: surgery, RT, CRT | ||||
| Gleich 55 | 2004 | 48 | HN | 20% (5 y) | 15% (5 y) | Local recurrence | |||
| Taussky 56 | 2005 | 17 | HN N |
76% | 24% | 46% (3 y) 13% (5 y) |
RT and CRT | ||
| Morgan 57 | 2007 | 38 | HN | 11% | 5% | Local compl 23% | |||
| Encinas 58 | 2007 | 26 | HN | 31% | Article not available | ||||
| Richey 39 | 2007 | 38 | HN | 24% | 42% (2 y) | 27-60% (1,2 y) |
|||
| Tan 16 | 2010 | 38 | HN | 63% | 43% (2 y) 37% (5 y) |
||||
| Inohara 36 | 2010 | 30 | HN | 30% | 7% | 74-87% (3 y) | |||
| Esteller 18 | 2011 | 32 | HN | 28% | 19% | 34% (5 y) | |||
| Simon 59 | 2011 | 21 | HN | 33% | 10% | ||||
| Leon 60 | 2015 | 24 | HN | 63% 13% |
26%(5 y) 70%(5 y) |
CRT Bioradiotherapy |
|||
| Present study | 22 | HN | 73% | 23% | 58% (5 y) | 27% (5 y) | 36% (5 y) | ||
| Davidson 27 | 1999 | 34 | N | 38% | 12% | 37% CRT | |||
| Stenson 61 | 2000 | 69 | N | 25% | 10% | ||||
| Newkirk 62 | 2001 | 33 | N | 13 CRT,20 RT. | |||||
| Grabenbauer 63 | 2003 | 56 | N | 25% | 4% | 44%(5 y) | 55% | Planned ND | |
| Kutler 64 | 2004 | N | ~30% | Only abstract | |||||
| Brizel 65 | 2004 | 52 | N | 8% major | 75% (4 y) | 77%(4 y) | Planned ND in N2-3. survival cCR | ||
| Frank 66 | 2005 | 39 | N | 5% surgical | |||||
| vd Putten 67 | 2007 | 61 | N | 79% (5 y) | 36% (5 y) | ||||
| Nouraei 68 | 2008 | 41 | N | 95% (5 y) | 64% (5 y) | Survival hemineck | |||
| Vedrine 69 | 2008 | 28 | N | 14% severe | |||||
| Christopoulos 70 | 2008 | 32 | N | 13% | |||||
| Lango 71 | 2009 | 65 | N | 18% | 5% | 55%CRT | |||
| Relic 45 | 2009 | 12 | N | 8% | |||||
| Hillel 72 | 2009 | 41 | N | 17% | |||||
| Bremke 73 | 2009 | 25 | N | 24% | |||||
| Goguen 28 | 2010 | 105 | N | 37% | |||||
| Robbins 74 | 2012 | 30 | N | 60% (5 y) | SSND, CRT | ||||
| Yirbesoglu 75 | 2013 | 44 | N | 71-73% (3 y) | 55-64% (3 y) |
*
Systematic review;
y: year; Com: complications, fistul: fistula, LR: locoregional control rate, OS: overall survival, DSS: disease specific survival, L: larynx, H: hypopharynx, HN: head and neck, N: neck, y: year, DFS: disease free survival, CRT: chemoradiotherapy, RT: radiotherapy, CT: chemotherapy, ND: neck dissection, PT: previous treatment, PL: partial laryngectomy, TL: total laryngectomy, primLE: primary laryngectomy, SSND: super selective neck dissection, st: studies, ICT: induction chemotherapy.